daytrades march 23 morning, page-159

for those who missed the ann on the 18/3 ANP ATL1101 for Prostate Cancer Update.... i like the word SUPRESS

As previously reported, Antisense Therapeutics Limited (ANP) is seeking to partner the further development
of its second generation antisense compound - ATL1101 for prostate cancer. This follows successful
animal studies where ATL1101 was shown to suppress human prostate tumour growth. These studies were
conducted as part of a collaborative research program with leading prostate cancer researcher, Professor
Martin Gleave at the Vancouver Prostate Cancer Centre.
As part of ANP?s strategy to partner ATL1101 and as previously reported, ANP had supplied ATL1101 drug
product to a specialist oncology company for the purpose of evaluating the compound in their animal
models of cancer. The Company evaluated ATL1101 in a different (non prostate) tumour system and
determined not to proceed with further experimental work on ATL1101.
This specific outcome does not affect ANP?s partnering plans for the further development of ATL1101 as a
treatment for prostate cancer as there is limited experience with the use of second generation antisense
drugs in the non prostate tumour system used in this case in comparison to the prostate cancer models
employed by Professor Gleave?s research group. Professor Gleave?s group also conducted preclinical
research on another 2nd generation antisense drug developed by OncoGenex Pharmaceuticals Inc. which
has since successfully completed Phase II trials in a range of cancers including prostate and is now in
Phase III clinical trials for prostate cancer.
Given Professor Gleave?s successful studies specifically related to the prostate cancer application of
ATL1101, ANP will continue to seek a development partner primarily for this indication. ANP is in
discussions with other parties interested in the development of ATL1101 for prostate cancer.
ANP has patent protection for ATL1101 to 2024, extendible up to 2029 in the US, Australia, Europe and
Japan.